Drug

Avixgen, a subsidiary of Dx&Vx, signs a licensing-out agreement worth USD 360 million with a U.S. biotech company for its next-generation drug delivery platform (ACP).

This innovative platform technology, with exceptional scalability, has been recognized as highly valuable even with limited rights granted.DXVX is taking...

Harrison Global Holdings Signs Strategic International Business Partnership Agreement with Biotree Co., Ltd., the World’s First Natural Product Drug Development Company for Metabolic Syndrome